CLCS (Cell Source) Additional Paid-In Capital: $27.60 Mil(As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CLCS Cell Source Inc CLCS
35 GF Score
Price $0.65
View Full Analysis

What is Cell Source Additional Paid-In Capital?

Cell Source CLCS 35 Additional Paid-In Capital is $27.60 Mil as of Dec. 2024. GuruFocus rates CLCS with a GF Score™ of 35/100.


Cell Source's quarterly additional paid-in capital declined from Jun. 2024 ($27.07 Mil) to Sep. 2024 ($26.86 Mil) but then increased from Sep. 2024 ($26.86 Mil) to Dec. 2024 ($27.60 Mil).

Cell Source's annual additional paid-in capital increased from Dec. 2022 ($23.67 Mil) to Dec. 2023 ($26.01 Mil) and increased from Dec. 2023 ($26.01 Mil) to Dec. 2024 ($27.60 Mil).

Cell Source Additional Paid-In Capital Related Terms

Cell Source Additional Paid-In Capital Historical Data

* Premium members only.

The historical data trend for Cell Source's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cell Source Additional Paid-In Capital Chart

Cell Source Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.73 21.32 23.67 26.01 27.60

Cell Source Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.01 26.15 27.07 26.86 27.60
CLCS
35GF Score
Cell Source Inc CLCS
Additional Paid-In Capital is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cell Source Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)
What does a Additional Paid-In Capital of $27.60 Mil mean?
Cell Source (CLCS) has a Additional Paid-In Capital of $27.60 Mil as of Dec. 2024. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Cell Source and its competitors.
Is Cell Source's Additional Paid-In Capital too high?
Cell Source's current Additional Paid-In Capital is $27.60 Mil. Overall, Cell Source has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Cell Source's Additional Paid-In Capital compare to EDSA and CTXR?
Cell Source's Additional Paid-In Capital of $27.60 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Additional Paid-In Capital for a Biotechnology company?
A good Additional Paid-In Capital depends on the Biotechnology industry context. However, Additional Paid-In Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Additional Paid-In Capital mean?
A high Additional Paid-In Capital can signal that a stock is expensive relative to its fundamentals. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Cell Source and its competitors. Cell Source's current Additional Paid-In Capital is $27.60 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cell Source stock overvalued right now?
Cell Source (CLCS) has a current Additional Paid-In Capital of $27.60 Mil. The current Additional Paid-In Capital is $27.60 Mil. Cell Source's overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Additional Paid-In Capital calculated?
Additional Paid-In Capital is calculated from a company's financial statements. For Cell Source (CLCS), the current Additional Paid-In Capital is $27.60 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cell Source Business Description

Address 57 West 57th Street, Suite 400, New York, NY, USA, 10019
Cell Source Inc is a biotechnology company focused on developing cell therapy treatments focused on immunotherapy. The company is involved with the development of proprietary immune system management technology. The company's subsidiary commercializes a suite of inventions relating to certain cancer treatments. The other products include Anti-rejection Veto Cell tolerance therapy for both matched and mismatched allogeneic bone marrow transplantations and Anti-rejection Veto Cell tolerance therapy for both matched as well as mismatched organ transplantation.
35GF Score

Get the complete analysis for CLCS

Additional Paid-In Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.65
Price